Doctors stunned after promising Novartis heart drug fails major study
The drug lowered lipoprotein(a), a genetic heart-risk factor, but did not cut heart attacks, strokes or cardiovascular deaths in a major trial.
For years, heart doctors believed they might finally have a new way to prevent heart attacks and strokes in millions of people.